<DOC>
	<DOCNO>NCT00094484</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety cinacalcet compare placebo patient stage 3 4 Chronic Kidney Disease ( CKD ) .</brief_summary>
	<brief_title>Cinacalcet HCl Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Chronic Kidney Disease patient receive dialysis : An iPTH great 100 pg/mL [ 10.6 pmol/L ] subject stage 3 CKD great equal 160 pg/mL [ 17.0 pmol/L ] subject stage 4 CKD ; A serum calcium great 9.0 mg/dL [ 2.25 mmol/L ] ; An estimate GFR less equal 59 mL/min great equal 15 mL/min . Have unstable medical condition , define hospitalize within 30 day day 1 , otherwise unstable judgment investigator . Experienced myocardial infarction ( MI ) within 3 month day 1 . Likely initiate dialysis ( opinion investigator ) schedule undergo renal transplantation within 28 week day 1 . Received active vitamin D therapy ( i.e. , 1hydroxylated metabolite vitamin D ) less 30 day day 1 require change active vitamin D brand dose level within 30 day day 1 ( patient prescribe active vitamin D ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Sensipar®</keyword>
	<keyword>Mimpara®</keyword>
	<keyword>Cinacalcet</keyword>
	<keyword>Calcimimetic</keyword>
	<keyword>Chronic Kidney Disease</keyword>
</DOC>